Most importantly, breast cancer patients with overexpression of Mortalin concomitant with advanced clinical stages and lymph node metastasis had a lower survival rate than those with low Mortalin expression. This evidence concerns the gene HSPA9 and metastatic malignant neoplasm in the lymph nodes.